Israeli biotech company Bonus Biogroup has announced that their lab-grown, semi-liquid bone graft has been successfully injected into the jaws of eleven people to repair bone loss in an early stage clinical trial (Reuters, 2016). The company’s Chief Executive Shai Meretzki said “For the first time worldwide, reconstruction of deficient or damaged bone tissue is achievable by growing viable human bone graft in a laboratory, and transplanting it back to the patient in a minimally invasive surgery via injection.”

The material, grown from each patient’s fat cells, was injected into and filled the voids of the problematic bones. Over a few months it hardened and merged with the existing bone to complete the jaw. Ora Burger, Bonus Biogroup’s vice president of regulation affairs, said the transplant “was 100 percent successful in all 11 patients. Now we are going to conduct a clinical study in the extremities, long bones.”

The announcement was made in a statement to the Tel Aviv Stock Exchange.

Bonus Biogroup presented its results at the International Conference on Oral and Maxillofacial Surgery in Madrid on December 5th.

Bonus Biogroup, which has raised $14m, plans to dual list on Nasdaq in the coming months.